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Gain-of-function mutations in the chloride channel ClC-2 were recently described as a cause
of familial hyperaldosteronism type II (FH-II). Here, we report the generation of a mouse
model carrying a missense mutation homologous to the most common FH-II-associated
CLCN2 mutation. In these Clcn2R180Q/+ mice, adrenal morphology is normal, but Cyp11b2
expression and plasma aldosterone levels are elevated. Male Clcn2R180Q/+ mice have
increased aldosterone:renin ratios as well as elevated blood pressure levels. The counterpart
knockout model (Clcn2−/−), in contrast, requires elevated renin levels to maintain normal
aldosterone levels. Adrenal slices of Clcn2R180Q/+ mice show increased calcium oscillatory
activity. Together, our work provides a knockin mouse model with a mild form of primary
aldosteronism, likely due to increased chloride efflux and depolarization. We demonstrate a
role of ClC-2 in normal aldosterone production beyond the observed pathophysiology.
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The adrenal steroid hormone aldosterone is an importantregulator of blood pressure and electrolyte homeostasis. Inthe kidney, its binding to the mineralocorticoid receptor
causes increased Na+ reabsorption via the apical epithelial
sodium channel ENaC and the basolateral Na+/K+-ATPase1,
raising blood pressure. This effect is accompanied by increased
K+ secretion via the apical ROMK channel2, lowering serum
potassium levels.
Excessive aldosterone production despite suppressed plasma
renin activity and normal or low extracellular potassium levels
(relative autonomy) is characteristic of primary aldosteronism
(PA), the most common cause of secondary hypertension3,4. It
accounts for about 6% of hypertensive patients in primary care
and about 10% in specialized hypertension centers5,6. Compared
with essential hypertension, PA is associated with an increased
risk of cardiovascular disease7,8. Approximately one third of PA
cases feature benign, typically unilateral tumors of the adrenal
gland (aldosterone-producing adenomas), caused by somatic
mutations in ion channels and pumps9–12. About two thirds have
bilateral adrenal hyperplasia (idiopathic hyperaldosteronism),
which may be due to an increased number and size of so-called
aldosterone-producing cell clusters that similarly carry somatic
mutations13–15.
Mendelian forms of PA are rare and often associated with early
onset16. Known forms are inherited in an autosomal−dominant
fashion and include familial hyperaldosteronism type I (FH-I)
with mutations in CYP11B2 (aldosterone synthase)17,18, FH-III
due to mutations in the potassium channel KCNJ59,19 and FH-IV
caused by mutations in the T-type voltage-gated calcium channel
CACNA1H20,21. Mutations in an L-type calcium channel (CAC-
NA1D) that is also expressed in the central nervous system are
found in a syndrome of PA, seizures, and neurologic
abnormalities10.
Recently, mutations in the chloride channel ClC-2 encoded by
the CLCN2 gene that is expressed in the zona glomerulosa were
identified as cause of FH-II22,23. This syndrome had initially
been described in an extended Australian kindred in 199224. By
exome sequencing of this kindred, we identified a heterozygous
CLCN2 mutation (p.Arg172Gln, located at the cytoplasmic end
of transmembrane helix C) that was present in eight subjects22;
incomplete penetrance was observed. In three additional unre-
lated kindreds with PA, the identical p.Arg172Gln was identified.
Further families showed mutations located in the N-terminus (p.
Met22Lys, p.Tyr26Asn), C-terminus (p.Ser865A), or the cyto-
plasmic interface of transmembrane helix K (p.Lys362del)22. In
an independent study, Fernandes-Rosa and colleagues identified
a single case with a de novo N-terminal p.Gly24Asp mutation23.
By electrophysiology in transfected mammalian cells or Xenopus
oocytes, all mutations were shown to cause gain of channel
function; mutant channels also led to increased aldosterone
production when expressed in an adrenocortical cancer cell
line22,23. The underlying pathophysiology of PA due to CLCN2
mutations was inferred to be increased chloride conductance of
glomerulosa cells (which have high intracellular chloride con-
centrations), depolarization, activation of voltage-gated calcium
channels, calcium influx, increased expression of aldosterone
synthase and PA22,23. Most recently, a somatic CLCN2 mutation
was found in a single aldosterone-producing adenoma25.
Mutations in adrenal ion channels appear to differ in their
ability to cause increased proliferation. KCNJ5 mutations that are
found in aldosterone-producing adenomas are typically asso-
ciated with massive bilateral adrenal hyperplasia when present in
the germline, requiring bilateral adrenalectomy9,19,26. In contrast,
germline mutations in the CACNA1H gene are associated with
only microscopic glomerulosa hyperplasia20. Some subjects with
CLCN2 mutations showed bulky adrenal glands or a small
adrenal nodule upon computed tomography, but in other cases,
adrenal imaging was unremarkable22, raising the question whe-
ther these mutations affect glomerulosa size in vivo and are
responsible for proliferation in aldosterone-producing tumors.
Besides the identification of CLCN2 mutations in PA, very little
has been known about any role of anion channels in zona glo-
merulosa (patho)physiology27,28. To investigate signaling path-
ways involved in PA and hypertension due to ClC-2 mutations,
we here generate and characterize a mouse model carrying a
heterozygous Clcn2 mutation at the position homologous to the
most common mutation in humans (p.Arg172Gln). We study the
effect of increased anion permeability on intracellular calcium, a
known determinant of glomerulosa aldosterone production27.
Here we show that Clcn2R180Q/+ mice have elevated Cyp11b2
expression and plasma aldosterone levels. Aldosterone:renin
ratios are elevated in male mice, and blood pressure is slightly
elevated, consistent with mild PA. The cellular correlate of these
findings is an increased calcium oscillatory activity in adrenal
glomerulosa cells. These results, combined with the finding of
elevated renin levels in Clcn2−/− mice, point to an important role
of ClC-2 in adrenal physiology and disease.
Results
Generation of Clcn2R180Q/+ mice. By sequence alignment, we
identified Arg180 in the mouse ClC-2 protein (NP_034030) as the
residue homologous to human Arg172 that is commonly mutated
in FH-II22. Mouse Arg180 is located in a highly conserved protein
region and is encoded by CGG as in humans (Fig. 1a). We
introduced a point mutation homologous to human Arg172Gln22
(chr16:20,712,754C > T (m38); p.Arg180Gln (NP_034030)) on
exon 5 of the mouse Clcn2 gene by using CRISPR/Cas9-based
genome editing (Fig. 1b, see Methods). Because FH-II is an
autosomal dominant disease with heterozygous mutations in
humans, mice with the heterozygous p.Arg180Gln mutation
(Clcn2R180Q/+, Fig. 1c, d) were used for further characterization.
Both male and female Clcn2R180Q/+ mice were viable and
fertile, and no obvious changes in morphology or behavior were
seen. Compared to C57BL/6N mice, no differences in litter size,
mortality rate until the age of 3 weeks or sex distribution among
litters were seen (Supplementary Fig. 1a–c). When Clcn2R180Q/+
mice were mated with WT mice, about half of surviving offspring
were Clcn2R180Q/+ (Supplementary Fig. 1d).
Whereas Clcn2−/− mice showed white matter vacuolization
and testicular degeneration as previously reported29,30, brain and
testis morphology were unremarkable in Clcn2R180Q/+ mice
(Supplementary Fig. 2).
Clcn2R180Q/+ mice show no zona glomerulosa hyperplasia.
Sanger sequencing of adrenal cDNA confirmed expression of the
mutant allele in the adrenal glands of Clcn2R180Q/+ mice (Fig. 1d).
Total adrenal weight was not significantly different in Clcn2R180Q/+
mice compared to controls (Fig. 2a). Similarly, by quantitative real-
time PCR, overall expression levels of Clcn2 in adrenal gland did
not differ between Clcn2R180Q/+ mice and controls (Fig. 2b), and
there was no sex dimorphism in Clcn2 expression (Fig. 2c). H&E
staining showed normal adrenal zonation and morphology in
Clcn2R180Q/+ mice (Fig. 2d, e). Qualitative assessment of Cyp11b2
expression and zona glomerulosa morphology using in situ hybri-
dization revealed no evidence of nodular glomerulosa hyperplasia
or formation of aldosterone-producing adenomas in Clcn2R180Q/+
mice (Fig. 3a, b).
Clcn2R180Q/+ mice have elevated aldosterone and Cyp11b2.
Plasma aldosterone levels were significantly increased (356.3 ±
23.96 pg ml−1 in Clcn2R180Q/+ mice versus 242.5 ± 17.57 pg ml−1
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in WT mice, mean ± SEM, P < 0.0001; one-way ANOVA,
Sidak´s multiple comparisons test (MCP)) (Fig. 4a, Table 1).
Aldosterone levels were similarly upregulated in female (WT: 267.4 ±
22.63 pgml−1; Clcn2R180Q/+: 361.5 ± 28.98 pgml−1; mean ± SEM; P
= 0.0323; one-way ANOVA, Bonferroni´s MCP) and male mice
(WT: 209.8 ± 26.29 pgml−1; Clcn2R180Q/+: 347 ± 43.61 pgml−1;
mean ± SEM; P= 0.0098; one-way ANOVA, Bonferroni´s
MCP) (Fig. 4b, Table 1). Accordingly, Cyp11b2 expression was 1.47
± 0.10-fold higher (mean ± SEM) in Clcn2R180Q/+ mice than in WT
mice (P= 0.0431; one-way ANOVA, Sidak´s MCP of log-
transformed fold change) (Fig. 4c) by real-time PCR. In subgroup
analysis, this effect was only seen in male, but not in female animals
(Fig. 4e).
In humans with PA and hypertension, renin levels are typically
suppressed, contributing to an elevated aldosterone:renin ratio
(ARR)4. PRC was unchanged between WT and Clcn2R180Q/+
mice, even in male and female subgroups (Fig. 4f, g, Table 1, see
Discussion). Whereas many mouse strains have two renin genes,
C57BL/6 only has Ren131. We thus examined relative renal
expression levels of the Ren1 gene in the kidney by quantitative
real-time PCR. No significant change in Ren1 expression was seen
in the entire Clcn2R180Q/+ group (1.16 ± 0.14-fold of WT, mean
± SEM, P= 0.9812; one-way ANOVA, Sidak´s MCP) (Fig. 4h),
but subgroup analysis showed suppression of Ren1 expression in
males (Fig. 4j).
Next, we calculated ARR from plasma aldosterone concentra-
tions and PRC levels (Fig. 5a, b). There was a non-significant trend
towards higher ARR levels in Clcn2R180Q/+ mice (Fig. 5a) (0.40 ±
0.05 pgml−1: ngml−1 h−1 vs. 0.25 ± 0.03 pgml−1: ngml−1 h−1 in
WT mice; mean ± SEM; P= 0.0511; Mann–Whitney test). Sub-
group analysis in male and female mice demonstrated significantly
increased ARR in male Clcn2R180Q/+ mice only (Fig. 5b) (0.59 ±
0.12 pgml−1: ng ml−1 h−1 vs. 0.26 ± 0.04 pgml−1: ngml−1 h−1
in WT mice; mean ± SEM; P= 0.001; one-way ANOVA, Bonfer-
roni´s MCP; see Discussion). Analogous to this ARR, we
calculated a Cyp11b2:Ren1 expression ratio (Fig. 5c, d). There
was no significant change in Cyp11b2:Ren1 expression ratios in the
entire cohort of Clcn2R180Q/+ mice (Fig. 5c) (1.67 ± 0.23 vs. 1.62 ±
0.40 in WT mice, mean ± SEM, P= 0.6338; Kruskal–Wallis test,
Dunn´s MCP), but subgroup analysis showed a significant
increase in male Clcn2R180Q/+ mice only (Fig. 5d) (4.40 ± 0.85
vs. 2.00 ± 0.70 in WT mice, mean ± SEM, P= 0.0039;
Kruskal–Wallis test, Dunn´s MCP). By quantitative real-time
PCR, expression levels of renal aldosterone targets (Slc12a3,
encoding the thiazide-sensitive carrier NCCT32, and Sgk1,
encoding serum and glucocorticoid-regulated kinase 1, upstream
of the epithelial sodium channel ENaC and the potassium channel
ROMK)33 were not significantly elevated in Clcn2R180Q/+ mice
compared to WT (Supplementary Fig. 3).
Clcn2R180Q/+ mice show decreased urinary sodium and
chloride. The majority of patients with PA do not have hypo-
kalemia4, and many patients with FH-II are similarly normoka-
lemic22. We determined plasma and spot urinary electrolytes
(potassium, sodium, chloride) in Clcn2R180Q/+ mice and WT
controls. Whereas no changes in plasma electrolytes or urinary
potassium levels were observed (Fig. 6a–d), urinary sodium
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Fig. 1 Generation of a heterozygous Clcn2R180Q/+ mouse model. a Alignment of human and mouse protein and genomic sequence surrounding human
Arg172 that is commonly mutated in FH-II. b Representation of the mouse Clcn2 locus with the targeted codon on exon 5. Sequence of gRNA to target the
Cas9 nuclease to exon 5 of the mouse Clcn2 gene is shown below the wildtype sequence. The PAM is underlined. The mutation is introduced by homology-
directed repair using a donor oligonucleotide (oligo), with the mutant codon shown in bold letters. c Sanger sequences of a Clcn2R180Q/+ mouse and a WT
control. d Sanger sequences of adrenal cDNA from a Clcn2R180Q/+ mouse and a WT control. gDNA, genomic DNA
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± SEM; P= 0.0032; one-way ANOVA, Sidak´s MCP, Fig. 6e)
and chloride levels (161.9 ± 10.97 mmol l−1 vs. 211.3 ±
12.65 mmol l−1 in WT; mean ± SEM; P= 0.0148; one-way
ANOVA, Sidak´s MCP, Fig. 6f) were lower in Clcn2R180Q/+
mice (Fig. 6b), suggesting increased retention, lower salt intake or
a more dilute urine. Interestingly, in subgroup analysis, this effect
was only significant in female, but not male mice.
Clcn2R180Q/+ mice have slightly elevated blood pressure. To
assess whether Clcn2R180Q/+ mice develop hypertension, we
measured blood pressure of unanaesthetized 3-month-old male
mice by telemetry, using catheters implanted in the carotid artery
(see Methods). Systolic and diastolic blood pressures as well as
mean arterial pressure (MAP) of Clcn2R180Q/+ mice were























































































































Fig. 2 Adrenal phenotype of Clcn2R180Q/+ mice. a Adrenal weights (normalized to body weight) are not significantly different between WT (N= 31; 0.22 ±
0.01 mg g−1) and Clcn2R180Q/+mice (N= 30; 0.22 ± 0.01 mg g−1; P= 0.599; Mann–Whitney test). b Adrenal expression of Clcn2 is unchanged in
Clcn2R180Q/+ compared to WT (Clcn2R180Q/+: N= 25, 1.24 ± 0.2, WT: N= 32, 1.34 ± 0.19; P= 0.8235; Unpaired t test of log-transformed fold change; t=
0.2241; df= 55). c Sex specific Clcn2 expression does not differ between WT and Clcn2R180Q/+ (female WT: N= 17, 1.4 ± 0.27; female Clcn2R180Q/+: N=
18, 1.5 ± 0.26, vs. female WT P= 0.8999; male WT: N= 15, 1.28 ± 0.26, vs. female WT P > 0.9999; male Clcn2R180Q/+: N= 7, 0.79 ± 0.14, vs. female
Clcn2R180Q/+ P= 0.3700, vs. male WT P= 0.7845; one-way ANOVA including Sidak´s MCP of log-transformed fold change; F= 1.492; df= 53). All data
(a–c) are specified as mean ± SEM in the legend; box plots are shown in the figure (box, interquartile range; whiskers, 1.5 times the interquartile range; line,
median; dots, outliers); N values are biologically independent animals. n.s., p > 0.05 d, e H&E stainings of adrenal sections show unaltered morphology of





























Cyp11b2 Control Cyp11b2 Control
Fig. 3 Cyp11b2 expression in adrenal glands of Clcn2R180Q/+ mice. Adrenal sections of WT and Clcn2R180Q/+ mice (one of six stainings each is shown.
C capsule, G glomerulosa, F fasciculata, M medulla) stained by in situ hybridization for Cyp11b2, with corresponding negative controls (see Methods).
(a) scale bar, 500 µm. (b) scale bar, 100 µm
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(systolic, 120.2 ± 0.1 mmHg versus 117.3 ± 0.1 mmHg; P= 0.028;
diastolic, 87.3 ± 0.1 mmHg versus 85.1 ± 0.1 mmHg; P= 0.041;
MAP, 103.3 ± 0.1 versus 100.8 ± 0.1; P= 0.033; all mean ± SEM
and Nested-model likelihood ratio comparisons). Similarly, heart
rate was elevated in Clcn2R180Q/+ (516.1 ± 0.7 BPM, mean ±
SEM) versus WT (497.6 ± 0.7 BPM; P= 0.002; Nested-model
likelihood ratio comparisons) (Fig. 7).
Clcn2R180Q/+ mice show an altered high-salt response. Hyper-
tension in states of high aldosterone is salt-dependent34, and
impaired suppression of aldosterone upon salt loading is diag-
nostic of PA in humans4. We therefore fed Clcn2R180Q/+ mice
and WT controls a high-salt diet (HSD) (1.71% sodium) for
4 weeks, added 1% NaCl to the drinking water, measured plasma
aldosterone as well as PRC and harvested adrenal glands and
kidneys for RNA extraction. Plasma aldosterone dropped after
HSD (Fig. 4a) in both genotypes, whereas PRC showed no sig-
nificant change (Fig. 4f). We next measured adrenal Cyp11b2
expression and renal Ren1 expression. This revealed incomplete
suppression of relative Cyp11b2 expression in Clcn2R180Q/+ mice
(2.85 ± 0.34) compared to WT mice (1.34 ± 0.23, mean ± SEM,
P < 0.0001; Mann–Whitney test) (Fig. 4d).
Aged Clcn2R180Q/+ mice show no evidence of end-organ
damage. To study whether elevated aldosterone levels in
Clcn2R180Q/+ mice are associated with end-organ damage, we
harvested kidneys and hearts from 11-month-old mice. H&E
staining (Supplementary Fig. 4), as well as staining for collagen
(fibrosis, Supplementary Fig. 5) or macrophages (inflammation,
Supplementary Figs. 6, 7) did not reveal qualitative differences
between Clcn2R180Q/+ mice and controls. Aged mice also did not
show evidence of adrenal hyperplasia (Supplementary Fig. 4).
Altered glomerulosa calcium signaling in Clcn2R180Q/+ mice.
Physiological stimuli of glomerulosa aldosterone production such
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Fig. 4 Clcn2R180Q/+ mice have elevated Cyp11b2 expression and plasma aldosterone levels. a, c, d Plasma aldosterone (WT: N= 37; Clcn2R180Q/+: N= 36;
P < 0.0001; one-way ANOVA, Sidak´s MCP; F= 4.161; df= 120) and Cyp11b2 expression (WT: N= 32, 1.23 ± 0.17; Clcn2R180Q/+: N= 25, 1.47 ± 0.1; P=
0.0431; one-way ANOVA, Sidak´s MCP of log-transformed fold change; F= 2.907; df= 63) are significantly increased in Clcn2R180Q/+ mice. Clcn2−/−
mice have unchanged plasma aldosterone (N= 10; P= 0.999; F= 4.313; df= 118) and Cyp11b2 expression (N= 10; P= 0.9959; both one-way ANOVA
including Sidak´s MCP; F= 2.907; df= 63). HSD leads to suppressed aldosterone levels in WT (WT: N= 37; HSD-WT: N= 19; P < 0.0001) and
Clcn2R180Q/+ (Clcn2R180Q/+: N= 36; HSD-Clcn2R180Q/+: N= 23; P < 0.0001; both one-way ANOVA, Sidak´s MCP; F= 4.313; df= 118). Cyp11b2 expression
is upregulated in Clcn2R180Q/+ compared to WT (HSD-WT: N= 24; HSD-Clcn2R180Q/+: N= 27; P < 0.0001; Mann–Whitney test). b, e Plasma aldosterone
is elevated in females (WT: N= 21; Clcn2R180Q/+: N= 23; P= 0.0323; df= 69) and males (WT: N= 16; Clcn2R180Q/+: N= 13; P= 0.0098; both one-way
ANOVA, Bonferroni´s MCP; F= 5.589; df= 69), Cyp11b2 expression is upregulated only in male Clcn2R180Q/+ (WT: N= 15; Clcn2R180Q/+: N= 7; P=
0.0275; one-way ANOVA including Sidak´s MCP; F= 1.782; df= 53). f, h, i PRC is unchanged (WT: N= 37, 1474 ± 245.3 ng ml−1 h−1, Clcn2R180Q/+: N=
36, 1334 ± 138.7 ng ml−1 h−1, P > 0.9999; HSD-WT: N= 19, 2830 ± 590.3 ng ml−1 h−1; HSD-Clcn2R180Q/+: N= 23, 1522 ± 218.4 ngml−1 h−1, P > 0.9999;
both Kruskal–Wallis test, Dunn´s MCP). Ren1 expression is unchanged (WT: N= 32, 1.17 ± 0.12; Clcn2R180Q/+: N= 27, 1.16 ± 0.14; P= 0.9812; one-way
ANOVA including Sidak´s MCP; F= 0.7894; df= 63; HSD-WT: N= 24, 1.26 ± 0.15; HSD-Clcn2R180Q/+: N= 27, 1.462 ± 0.23; P= 0.9813; Mann–Whitney
test). In Clcn2−/−, the expression of Ren1 (WT: N= 32, 1.17 ± 0.12; Clcn2−/−: N= 10, 2.1 ± 0.32; P= 0.0125; one-way ANOVA including Sidak´s MCP; F=
0.7894; df= 63) and PRC (WT: N= 37, 1474 ± 245.3 ng ml−1 h−1; Clcn2−/−: N= 10, 2602 ± 546.1 ng ml−1 h−1; P= 0.03; Kruskal–Wallis test, Dunn´s
MCP) are significantly upregulated compared to WT. g, j Female (WT: N= 21, 1839 ± 392 ngml−1 h−1; Clcn2R180Q/+: N= 23, 1589 ± 166.3 ng ml−1 h−1; P >
0.9999;) as well as male mice (WT: N= 16, 995.1 ± 194.7 ng ml−1 h−1; Clcn2R180Q/+: N= 13, 882.6 ± 198 ngml−1 h−1; P > 0.9999; both Kruskal-Wallis
test; Dunn´s MCP) show no significant alteration in PRC. Ren1 expression is significantly downregulated in male Clcn2R180Q/+ mice only (WT: N= 15, 1.14
± 0.16; Clcn2R180Q/+: N= 7, 0.57 ± 0.07; P= 0.0158; one-way ANOVA including Sidak´s MCP; F= 0.6378; df= 53). Mean ± SEM for all data in the legend;
box plots (box, interquartile range; whiskers, 1.5 times the interquartile range; line, median; dots, outliers) are shown in the figure; N values are biologically
independent animals. NSD, normal salt diet. *, p < 0.05; **, p < 0.01; ****, p < 0.0001; n.s., p > 0.05
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calcium concentration27, and similar mechanisms have been
suggested to underlie hyperaldosteronism in subjects with CLCN2
mutations22,23. To detect relative changes in intracellular glo-
merulosa calcium concentrations in Clcn2R180Q/+ mice and WT
controls, we loaded acute adrenal slice preparations with the
fluorescent and cell-permeable calcium indicator Calbryte 520
AM (see Methods) and studied cellular responses to changes in
extracellular K+ and AT-II. In the absence of AT-II, only a
negligible number of cells showed calcium spikes in both strains,
in agreement with previous reports for WT mice35. Increasing
[AT-II] to 20 pM in the perfusion solution (similar to levels in
healthy humans36; 50 pM have been reported in mice37) resulted
in visible activity in some cells, either as single, isolated spikes or
as temporally clustered bursts of activity (burst plots in Fig. 8a, b;
Supplementary Movies 1 and 2). Raising the concentration of AT-
II above physiological levels to 1 nM further increased the extent
of bursting activity (Fig. 8a, b).
To examine whether calcium signaling in Clcn2R180Q/+
mice is altered, we assessed the oscillatory activity in
individual cells. To account for the potential lack of
independence between cells from the same animal, linear
mixed modeling was performed as described in Methods. The
number of spikes in the absence of AT-II was insufficient for
statistical analysis. Mean activity was significantly higher in
Clcn2R180Q/+ mice than in WT mice at 3 mM [K+], both for
20 pM AT-II (mean ± SD Clcn2R180Q/+ vs. WT: 0.0234 ±
0.0478 vs. 0.0038 ± 0.0130 s−1 cell−1, χ2(1)= 5.3413, P=
0.0208, N= 134/134; likelihood ratio test) and 1 nM AT-II
(0.2163 ± 0.1568 vs. 0.1247 ± 0.1114 s−1 cell−1, χ2(1)= 11.97,
P= 0.0005, N= 157/134; likelihood ratio test). This was also
the case at additional stimulation with 5 mM [K+] for 1 nM
AT-II (0.3191 ± 0.2003 vs. 0.1830 ± 0.1445 s−1 cell−1, χ2(1)=
8.3487, P= 0.0039, N= 154/134; likelihood ratio test)






































































































































































































Fig. 5Male Clcn2R180Q/+ mice have elevated aldosterone:renin ratios. a Aldosterone:renin ratios (ARR) were calculated using values of plasma aldosterone
levels and PRC. No significant differences were detected for Clcn2R180Q/+ mice compared to WT under normal salt (WT: N= 37; Clcn2R180Q/+: N= 36;
P= 0.5892) as well as after HSD (HSD-WT: N= 19; HSD- Clcn2R180Q/+: N= 23; P= 0.3788; both Kruskal-Wallis test, Dunn´s MCP). In addition, ARR of
Clcn2−/− mice was not significantly changed compared to WT (WT: N= 37; Clcn2−/−: N= 10; P= 0.2089; Kruskal–Wallis test, Dunn´s MCP). b Subgroup
analysis showed increased ARR levels in male Clcn2R180Q/+ mice compared to WT (WT: N= 16; Clcn2R180Q/+: N= 13; P= 0.0010; one-way ANOVA
including Bonferroni´s MCP; F= 6.896; df= 69), but not in female mice (WT: N= 21; Clcn2R180Q/+: N= 23; P= 0.8346; one-way ANOVA
including Bonferroni´s MCP; F= 6.896; df= 69). c A ratio of Cyp11b2 and Ren1 expression was calculated using fold change. There is no significant
difference between Clcn2R180Q/+ and WT mice as well as Clcn2−/− compared to WT (WT: N= 32; Clcn2R180Q/+: N= 25; P= 0.8622; Clcn2−/−: N= 10,
P= 0.6780; Kruskal–Wallis test, Dunn´s MCP). After HSD, the ratio was slightly increased in Clcn2R180Q/+ mice compared to WT (HSD-WT: N= 24;
HSD-Clcn2R180Q/+: N= 27; P= 0.0711; Kruskal–Wallis test, Dunn´s MCP). d The ratio was significantly increased in male Clcn2R180Q/+ mice compared
to WT (WT: N= 15; Clcn2R180Q/+: N= 7; P= 0.0039; Kruskal–Wallis test and Dunn´s MCP), but not in female mice (WT: N= 17; Clcn2R180Q/+: N= 18;
P > 0.9999; Kruskal-Wallis test and Dunn´s MCP). All data are shown in box plots (box, interquartile range; whiskers, 1.5 times the interquartile range; line,
median; dots, outliers); N values are biologically independent animals. **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; n.s., p > 0.05
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as a major factor in the pathogenesis of elevated aldosterone
levels in Clcn2R180Q/+ mice.
Clcn2R180Q/+ increases [AT-II]-dependent calcium bursting.
As activity in cells appears to be clustered, we defined bursts of
calcium activity based on interspike interval analysis (see
Methods). Again, analysis was performed using a linear mixed
model to account for potential non-independence of cells from
the same animal (see Methods). The number of calcium bursts
per second and cell was significantly increased in Clcn2R180Q/+
mice compared to WT at 1 nM AT-II for both, 3 and 5 mM of
K+ (Supplementary Fig. 8a). A trend towards an increased
number of bursts at 20 pM of AT-II was not significant (Sup-
plementary Fig. 8a). Burst duration was not significantly altered
(Supplementary Fig. 8b), and within bursts, the spiking fre-
quency did not significantly differ between Clcn2R180Q/+ mice
and controls (Supplementary Fig. 8c). These results suggest that
the augmented ClC-2 activity in Clcn2R180Q/+ mice mainly
increases the likelihood of initiating bursting activity in the
presence of AT-II, likely through depolarization compared to
wildtype controls.
Clcn2−/− mice show increased renin levels. To study whether
ClC-2 plays a role in physiological aldosterone production
beyond FH-II, we investigated Clcn2−/− mice29. Knockout mice
had unaltered plasma aldosterone levels and Cyp11b2 expression
(Fig. 4a, c). However, this occurred at the expense of elevated
PRC and renal Ren1 expression (Fig. 4f, h), suggesting that
activation of the renin-angiotensin system is required to maintain
normal aldosterone levels in Clcn2−/− mice, and that ClC-2 is
involved in normal zona glomerulosa function.
Discussion
The Clcn2R180Q/+ mouse model characterized here represents a
genetic mouse model of FH-II with a rather mild phenotype.
Previously characterized genetic mouse models with elevated
aldosterone levels include a line derived from a mutagenesis
screen with mutations in several candidate genes38, TASK
channel knockout mice that so far lack a human Mendelian
disease counterpart35,39–42, cryptochrome-null mice43 with
pathophysiology that largely differs from that in known forms of
human Mendelian aldosteronism and a recently published
transgenic mouse model that expresses human CYP11B2 under
the control of a human CYP11B1 promoter similar to the situa-
tion in FH-I44. A mouse model of FH-III did not consistently
replicate the human phenotype (adrenal hyperplasia and elevated
aldosterone levels)45.
The model described herein reproduces features of FH-II in
humans, albeit with a less severe phenotype than in human index













































































































































































































































































Fig. 6 Plasma and urine electrolyte levels. Plasma levels of potassium (a) (WT: N= 10; Clcn2R180Q/+: N= 16; P= 0.9315; female WT: N= 6; female
Clcn2R180Q/+: N= 10; P= 0.5490; male WT: N= 4; male Clcn2R180Q/+: N= 6; P= 0.9161; one-way ANOVA including Sidak´s MCP; F= 1.02; df= 46),
sodium (b) (WT: N= 10; Clcn2R180Q/+: N= 16; P= 0.9854; female WT: N= 6; female Clcn2R180Q/+: N= 10; P= 0.9956; male WT: N= 4; male
Clcn2R180Q/+: N= 6; P= 0.7652; one-way ANOVA including Sidak´s MCP; F= 0.4119; df= 46) and chloride (c) (WT: N= 10; Clcn2R180Q/+: N= 16; P=
0.5559; female WT: N= 6; female Clcn2R180Q/+: N= 10; P= 0.9658; male WT: N= 4; male Clcn2R180Q/+: N= 6; P= 0.4857; one-way ANOVA including
Sidak´s MCP; F= 0.5725; df= 46) do not differ between WT and Clcn2R180Q/+ mice. Urinary potassium (d) is not changed in Clcn2R180Q/+ mice (WT:
N= 13; Clcn2R180Q/+: N= 20; P= 0.7833; female WT: N= 7; female Clcn2R180Q/+: N= 10; P= 0.5567; male WT: N= 6; male Clcn2R180Q/+: N= 10; P >
0.9999; one-way ANOVA including Sidak´s MCP; F= 0.9392; df= 60). In contrast, urine levels of sodium (e) (WT: N= 13; Clcn2R180Q/+: N= 20; P=
0.0032; female WT: N= 7; female Clcn2R180Q/+: N= 10; P= 0.0030; male WT: N= 6; male Clcn2R180Q/+: N= 10; P= 0.0819; one-way ANOVA including
Sidak´s MCP; F= 1.617; df= 60) and chloride (f) (WT: N= 13; Clcn2R180Q/+: N= 20; P= 0.0148; female WT: N= 7; female Clcn2R180Q/+: N= 10; P=
0.0064; male WT: N= 6; male Clcn2R180Q/+: N= 10; P= 0.7609; one-way ANOVA including Sidak´s MCP; F= 0.4131; df= 60) show significant
decreases in Clcn2R180Q/+ overall and in female mice. All data are shown in box plots (box, interquartile range; whiskers, 1.5 times the interquartile range;
line, median; dots, outliers); N values are biologically independent animals. *, p < 0.05; **, p < 0.01; n.s., p > 0.05
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Fig. 7 Clcn2R180Q/+ mice have higher blood pressure. Blood pressure (BP) and heart rate (HR) of animals assessed through telemetry sensors. Shown are
loess regressions of BP/HR of WT (black, N= 11 biologically independent animals) and Clcn2R180Q/+ (red, N= 11 biologically independent animals)
animals, with gray intervals denoting 95% confidence intervals for loess regressions. Horizontal axis shows time, with black markers noting nights (6 p.m.
to 6 a.m., active periods of nocturnal animals). Horizontal lines show mean for the entire measurement period for WT (black dash-dotted) and
Clcn2R180Q/+ (red dashed) animals. Nested-model likelihood ratio comparisons reveal significantly higher BP (systolic, P= 0.028; diastolic P= 0.041,
MAP, P= 0.033) and HR (P= 0.002) of Clcn2R180Q/+ animals than WT. Average (mean ± SEM for all) systolic BP is 117.3 ± 0.1 mmHg (WT) and 120.2 ±
0.1 mmHg (Clcn2R180Q/+). Average diastolic BP is 85.1 ± 0.1 mmHg (WT) and 87.3 ± 0.1 mmHg (Clcn2R180Q/+). Average MAP is 100.8 ± 0.1 mmHg (WT)
and 103.3 ± 0.1 mmHg (Clcn2R180Q/+). Average HR is 497.6 ± 0.7 BPM (WT) and 516.1 ± 0.7 BPM (Clcn2R180Q/+)
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in blood pressure and incomplete suppression of aldosterone
synthase expression upon high-salt challenge (1.71% sodium diet,
corresponding to the very high end of the spectrum of human salt
consumption46,47). A trend towards elevated aldosterone levels in
Clcn2R180Q/+ mice after HSD was not significant, possibly due to
small sample sizes. Unlike in most humans with FH-II, PRC was
not suppressed in Clcn2R180Q/+ mice, likely due to only slightly
elevated blood pressure. In line with this interpretation, male
Clcn2R180Q/+ mice (with more severe phenotype) showed sig-
nificantly lower Ren1 expression levels than WT mice. Similar
observations (mildly elevated aldosterone, normal plasma renin
concentration (PRC)) have been made in mice with tissue-specific
deletion of TASK channels42. In such a setting, extended periods
of high-salt treatment might be necessary to produce end-organ
damage48,49. Unlike aldosterone synthase-transgenic mice with
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Fig. 8 Clcn2R180Q/+ mice have altered glomerulosa calcium signaling. a, b Left, representative average projection of 10 frames (1 s) without AT-II of a
recording of calcium signals from acute adrenal slice preparations of either (a) wildtype (WT) or (b) Clcn2R180Q/+ mice (R180Q). Scale bar: 50 µm.
Borders of the capsule (C), zona glomerulosa (ZG) and the outer part of the zona fasciculata (ZF) are shown in orange. Bright white spots likely correspond
to apoptotic cells. Cells (yellow outlines) were selected from the recording, and mean intensity values over time were extracted. Top right, activity of all
selected cells is shown in a burst plot. Cells are separated in rows along the y-axis, with time displayed along the x-axis. Detected spikes of the calcium
signal are plotted as vertical lines with multiple spikes in close proximity merging into longer bars. Extracellular solution was perfused continuously and
changed at the time points indicated. Representative examples of variations in the fluorescence recorded at 1 nM of AT-II are shown in a magnified inset.
(c) Violin plots of cellular activity (WT in orange, Clcn2R180Q/+ in blue) in the zona glomerulosa as determined by the number of spikes per cell and second.
All data points are shown, a black horizontal bar denotes the mean of the distribution. (N (cells): 3 mM [K+], no AT-II – WT: N= 126, Clcn2R180Q/+ N=
134, not tested; 3 mM [K+], 20 pM AT-II - WT: N= 134, Clcn2R180Q/+ N= 134, χ2(1)= 5.3413, P= 0.0208 (*); 3 mM [K+], 1 nM AT–II - N= 157,
Clcn2R180Q/+ N= 134; χ2(1)= 11.97, P= 0.0005 (***); 5 mM [K+], no AT-II – WT: N= 150, Clcn2R180Q/+ N= 134, not tested; 5 mM [K+], 20 pM AT-II -
WT: N= 153, Clcn2R180Q/+ N= 134, χ2(1)= 3.2957, P= 0.0695 (n.s.); 5 mM [K+], 1 nM AT–II - N= 154, Clcn2R180Q/+ N= 134, χ2(1)= 8.3487, P=
0.0039 (**); likelihood ratio test)
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not show upregulation of renal aldosterone target gene expression
by real-time PCR. Interestingly, ARR was only elevated in male,
but not in female mice. We excluded differences in Clcn2
expression as cause of this observed sex dimorphism. Changes
during the mouse estrus cycle may cause increased variability in
parameters of the renin–angiotensin–aldosterone system in
female rodents50; in humans, aldosterone levels rise during the
luteal phase51. In addition, sex dimorphism in adrenocortical
tissue renewal was recently described, with female mice showing a
3-fold higher turnover than males52, and sex dimorphism has
previously been reported in a mouse model of PA41.
The rather mild phenotype observed in mice is consistent with
incomplete penetrance in humans22: In FH-II families, index
cases typically had severe hyperaldosteronism and hypertension,
which may be due to selection bias. However, in a large Aus-
tralian kindred, three of eight mutation carriers did not have
hypertension. Among these three subjects, ARRs were normal in
one individual, borderline in a second and elevated in the third.
These considerations suggest that factors other than the CLCN2
mutation contribute to disease expression. The mild phenotype of
Clcn2R180Q/+ mice could allow for the identification of such
elusive genetic, epigenetic and/or environmental modifiers:
Investigation of congenic mouse strains as well as effects of
the microbiome or food on aldosterone levels and blood pressure
would be instrumental53. A weakness of the current model is the
absence of cardiac or renal damage. Homozygous mice
(Clcn2R180Q/R180Q) may show a more severe phenotype and could
enable studies of target organ damage.
The absence of macroscopic or microscopic adrenal hyper-
plasia in Clcn2R180Q/+ mice suggests that CLCN2 mutations in
humans and in mice may have a predominant effect on aldos-
terone synthesis rather than cellular proliferation; microscopic
images of FH-II patients were unavailable22. A CLCN2 mutation
has only very recently been described in an aldosterone-
producing adenoma; however, this was small tumor25, similar
to those with CACNA1D and ATPase mutations.
The Clcn2R180Q/+ mouse model also allowed us to further
investigate the impact of the mutation on the cellular level. Cal-
cium imaging in acute slice preparations revealed only very low
activity of the zona glomerulosa in unstimulated adrenal glands
from either WT or Clcn2R180Q/+ mice, similar to results in WT
mice by Penton and colleagues35. Stimulation with AT-II led to
an increase in calcium signaling and the appearance of calcium
bursts, further defining the mechanism by which aldosterone
synthesis is regulated under physiological conditions; Penton and
colleagues even observed continuous activity without intermittent
silent periods upon stimulation with extremely high AT-II and
K+ concentrations. Clcn2R180Q/+ mice showed an increase of the
mean activity per cell compared to controls in the presence of
AT-II, demonstrating a higher sensitivity for stimulation,
accounting for the increased aldosterone production in mice and
patients. A significant increase in the number of bursts could only
be observed at 1 nM of AT-II while the trend was also visible at 20
pM but not significant, likely due to the smaller overall number of
bursts and small effect size. In contrast, frequencies during
bursting and burst lengths remained unchanged. These results
support a main role of ClC-2 in cellular depolarization22 and
initiation of calcium signals in the form of bursts.
Future studies may compare the phenotype, adrenal mor-
phology and calcium signaling of the Clcn2R180Q/+ model with
other models of familial hyperaldosteronism. Mouse models with
gain-of-function mutations in calcium channels have so far not
been described, but would be particularly interesting to assess.
The physiological role of ClC-2 in zona glomerulosa function,
suggested by elevated renin expression in Clcn2 knockout mice,
also warrants further investigation.
Methods
Generation of the mouse model. The mouse model C57BL/6N-Clcn2em1Uis
(Clcn2R180Q/+) was generated by Cyagen Biosciences, Inc., using the CRISPR/Cas9
technology. The guide RNA (gRNA) was 5′-CAGCACCACTCCCCGAAGG
ATGG-3′ (protospacer adjacent motif (PAM) sequence underscored). A donor
oligonucleotide was used to mutate CGG encoding Arg180 (NM_009900.2) to
CAG (encoding Gln) by homology-directed repair (5′-ATGCTCCTGGGAACAT
GTATCTCTGCAGGGTCTGGCATCCCCGAAATGAAAACCATCCTTCAGGG
AGTGGTGCTGAAAGAATACCTCACCCTCAAGACCTTTGTAGCTAAGGTC
ATTGGGCTA-3′; mutated codon underscored). gRNA and Cas9 mRNA were
generated by in vitro transcription and co-injected with the donor oligonucleotide
into 460 fertilized eggs, followed by embryo transfer. Thirteen of 15 surrogates
became pregnant. The offspring was genotyped by PCR (Clcn2-F: 5′-GTCTTATC
ATTGTGTCCCAGTGGCAG-3′; Clcn2-R: 5′- ATCTCCGTGTTCCGGGACTCA
TG-3′) and Sanger sequencing (5′-GGGGCTTAAACACCAACATCTTACTC-3′).
Three of 60 pups carried a heterozygous p.Arg180Gln variant without additional
frameshift variants. In the two mice used for further breeding, mutations in the five
top off-target sites were excluded by Sanger sequencing (Supplementary Table 1).
To genotype further generations, primers Mouse Clcn2-F: 5′-GTGTCCCAGTGGC
AGGCAAGG-3′ and Mouse Clcn2-R: 5′-CAGTGTCAGCTTGGGCTCAGCAG-3′
were used. Animals were backcrossed to C57BL/6N three times before experiments
were conducted.
Clcn2R180Q/+ mice can be obtained exclusively for non-commercial research
purposes (material transfer agreement). Recipients must treat, keep and use mice
according to applicable regulations (e.g., animal welfare and protocols) and pay for
packing, shipping, and handling. Recipients must not distribute the mice, their
progeny or other materials derived from these mice without written consent of the
provider and must cite this publication.
Animals and sample collection. The Clcn2−/− strain was kindly provided by Dr.
Thomas Jentsch, the generation of this mouse model was described by Bösl et al.29.
All strains were bred and housed at the Zentrale Einrichtung für Tierforschung und
wissenschaftliche Tierschutzaufgaben (Heinrich Heine University Düsseldorf), the
Forschungseinrichtungen für Experimentelle Medizin (Charité—Uni-
versitätsmedizin Berlin) and/or the Forschungszentrum Jülich (only Clcn2R180Q/+
mice studied at age 11 months). They were maintained under specific pathogen-
free conditions in a 12-h light/dark cycle with ad libitum access to food and water.
All animal experiments were approved by the local authorities (Landesamt für
Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen and Landesamt für
Gesundheit und Soziales Berlin) and performed under consideration of all relevant
ethical regulations.
To harvest organs for RNA extraction, mice were anesthetized using ketamine
100 mg kg−1+ xylazine 10 mg kg−1 i.p., followed by cervical dislocation. After
opening of the thoracic cavity, blood was collected by cardiac puncture and
transferred into Vacutainer EDTA tubes (Becton Dickinson). Blood samples were
centrifuged (10 min, 2000g, 4 °C), and the supernatant (plasma) was stored at
-20 °C until further analysis. Adrenal glands were harvested and weighed, and
kidneys and brains were collected. All organs were stored in tubes containing
RNAlater RNA stabilization reagent (Qiagen; 4 °C overnight, then -20 °C) until
RNA extraction. For histology, animals were anaesthetized using ketamine 100 mg
kg−1+ xylazine 10 mg kg−1 i.p., and organs were fixed by cardiac perfusion. A 23G
blood collection set (Becton Dickinson) was inserted into the left ventricular
chamber. After opening of the right atrium, the heart was perfused with 10 mL PBS
containing 10 U/mL heparin, followed by 10 mL 4% paraformaldehyde in PBS (pH
7.4; Santa Cruz). Adrenal glands were harvested and weighed. In addition, kidneys,
brains, hearts, and testis were removed. All organs were fixed in 10% formalin
solution (neutral buffered; Sigma Aldrich) for 18–24 h. 11-month-old mice were
anesthetized with isoflurane (1 ml/l open drop). Following cervical dislocation,
hearts, kidneys, and adrenal glands were harvested and kept in PBS+ 0.03% NaN3
for 72 h after fixation until further processing. Samples were dehydrated in ethanol
(70%, 80%, 96%, and 100%) and xylene, followed by embedding into paraffin
(Merck Millipore) and storage at 4 °C (for in situ hybridization) or room
temperature until further investigations. Spot urine was collected over three days in
the morning followed by 1 week of recovery and blood collection via cardiac
puncture (26G needle, 1 ml syringe) into Microtainer (Lithium-Heparin) tubes
(Becton Dickinson). One group of mice per genotype received a HSD (E15431–34
containing 1.71% sodium, Ssniff Spezialdiäten) and 1% NaCl via drinking water for
4 weeks. Mice were euthanized by cervical dislocation under anesthesia, and blood
and organs were collected as above.
Quantitative real-time PCR. Total RNA from adrenal glands and kidneys was
isolated using the miRNeasy Mini Kit (Qiagen). Concentration and purity was
assessed with a Nanodrop 2000 (Thermo Scientific). After reverse transcription of
RNA using Quantitect RT Kit (Qiagen), Taqman gene expression assays (Applied
Biosystems) for Gapdh (Mm99999915_g1, housekeeping gene), Cyp11b2
(Mm00515624_m1) and Clcn2 (Mm01344259_m1) were performed for adrenal
samples. Gapdh (primers 5′-TGTAGACCATGTAGTTGAGGTCA-3′ and 5′-AGG
TCGGTGTGAACGGATTTG-3′), Ren1 (5′-TCTGGGCACTCTTGTTGCTC-3′
and 5′-GGGGGAGGTAAGATTGGTCAA-3′), Slc13a2 (5′-CGAGAGTAATCCA
GCAGTA-3′ and 5′-ATGAAGAGATTAACAAGAACAGAA-3′)54 and Sgk1
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(5′-ATGCAGTAAACCAGCCGGT-3′ and 5′-TGATCCATCTTCGTACCCGT-3′)
were amplified from kidney cDNA using Power SYBR Green PCR Master Mix
(Applied Biosystems). Gene expression was evaluated relative to Gapdh, and mean
ΔCT of WT controls and expressed as 2ΔΔCt (fold change).
H&E and Sirius red staining. Formalin-fixed, paraffin-embedded (FFPE) adrenal
glands, kidneys, brains, hearts and testes of 12 to 16 weeks old (WT, Clcn2R180Q/+),
9 weeks old (Clcn2−/−29) and 11-month-old mice (WT, Clcn2R180Q/+) were cut
into 5 µm sections. After deparaffinization by xylene and rehydration in ethanol
(100%, 95%, 90%, 80%, and 70%) and deionized water, the sections were incubated
in hematoxylin (Sigma Aldrich) for 3 min. Sections were rinsed in tap water,
dipped 8–12x in acid ethanol (0.25% HCl in 70% ethanol), incubated in eosin (Carl
Roth) for 30 s, dehydrated in 100% ethanol and mounted using VectaMount
(Vector Labs).
For Sirius red staining, sections of 11-month-old mice were deparaffinized and
rehydrated as above, incubated in hematoxylin for 8 min and washed in tap water
for 5 min. Sections were incubated in 0.25 g/L Direct Red 80 (Sigma Aldrich) in
1.3% picric acid (Sigma Aldrich) for 60 min, washed in 0.5% acetic acid for 1 min,
dehydrated (70%, 95% and 100% ethanol and xylene) and mounted using
VectaMount.
In situ hybridization. Cyp11b2 in situ hybridization in FFPE adrenal glands was
performed using the RNAscope 2.5 HD Assay - Brown (Advanced Cell Diag-
nostics). 5 µm sections were treated according to the manufacturer’s instructions
(document numbers: 322452 and 322310-USM). Probes were Mm-Cyp11b2 (Cat
No. 505851), and DapB (Cat No. 310043, negative control).
Immunohistochemistry. 5 µm kidney or heart sections of 11-month-old mice
(WT, Clcn2R180Q/+) were heated at 60 °C for 1 h, deparaffinized using xylene and
rehydrated in ethanol (100%, 95%, 90%, 80%, and 70%) and deionized water. After
antigen retrieval by boiling two times in 10 mM sodium citrate+ 0.05% Tween 20
in H2O (pH 6.0) and 15 min incubation after each boiling, sections were per-
meabilized in 0.2% Triton X-100 in PBS (15 min), incubated in 3% H2O2 in PBS to
remove peroxidase (10 min) and blocked using 10% BSA (Sigma Aldrich, St. Louis,
MO, USA) in PBS for 1 h, followed by incubation with primary antibody against
F4/80 (1:100; sc-377009 HRP; Santa Cruz) overnight at 4 °C (10% BSA in PBS was
used for corresponding controls). After DAB staining (Becton Dickinson) for 30 s
and counterstaining using hematoxylin (Sigma Aldrich) for 10 min, slides were
mounted with VectaMount.
Aldosterone ELISA. Plasma aldosterone levels were measured by enzyme-linked
immunosorbent assay (ELISA, RE52301; IBL International GmbH) according to
the manufacturer’s instructions.
Determination of PRC. PRC was determined by measuring the capability of the
sample to generate Angiotensin I (AT-I) from excess renin substrate55. AT-I
concentrations were determined using a radioimmunoassay (RIA) with the fol-
lowing modifications: high binding RIA tubes (Greiner Bio-One) were coated with
300 µl of 1:60,000 diluted anti-AT-I antibodies for 20 h at 4 °C. After washing with
TRIS buffer, tubes were incubated with 400 µl blocking buffer containing 0.5% BSA
for 2 h at room temperature to prevent unspecific binding. Tubes were washed
again and stored at -20 °C. For the RIA, 3 × 50 µl of the pre-treated samples and
200 µl 125I-labeled AT-I with an activity of 5000 cpm (Amersham Biosciences)
were added to the coated tubes und incubated for 20 h at room temperature. After
three times washing with 1 ml washing buffer, the AT-I concentration was mea-
sured using a γ-counter (Berthold LD 2111). The concentration was determined
according to the standard curve.
Determination of electrolytes. Plasma and urine electrolytes (K+, Na+, Cl−) were
measured at the Animal Phenotyping Facility at Max-Delbrück-Centrum (MDC)
Berlin using an AU480 Clinical Chemistry Analyzer (Beckman Coulter).
Blood pressure measurements. Blood pressure was measured via telemetry. A
telemetric catheter (DSI PhysioTel PA-C10; weight 1.4 g; Data Science Interna-
tional) was implanted in 3-month-old male mice under general anesthesia using
ketamine 100 mg kg−1+ xylazine 10 mg kg−1 i.p. Via a median neck incision, the
right common carotid artery was located and dissected. The carotid artery was
ligated near the bifurcation, and two loops were placed caudal to the ligature.
Caudally the blood flow of the common carotid artery was stopped using a min-
iature clamp, an angled cannula tip was inserted, and the catheter was placed into
the vessel. After releasing the mini clamp, the catheter was pushed forward by
1.5 cm towards the aortic bifurcation and fixed by closing the loops. A sub-
cutaneous cavity was prepared for the transmitter. The wound was closed using
3–0 Prolene. Rimadyl 5 mg/kg s.c. was given intraoperatively and on the first,
second, and third postoperative day. Mice were fed a standard diet (V1124-300
containing 0.24% sodium, ssniff Spezialdiäten). After 1 week of recovery, blood
pressure and heart rate were recorded for ten days (every 5 min, each 10 s).
Locomotor activity was recorded based on signal strength changes that occurred
with changes in the orientation of the animal relative to the receiver or changes in
the distance of the animal from the receiver. Quality controlled sensor data were
analyzed by mixed effect modeling using the lme456 R package, with animal and
time of day as random effects, day-night status and genotype as fixed effects.
Significance of genotype, correcting for activity, was done through likelihood ratio
test comparison with a model omitting the tested predictor as implemented in the
lmtest57 R package. Blood pressure data were plotted as loess regressions using the
ggplot258 R package, separately by genotype, showing 95% confidence interval of
loess parameters in the figure.
Calcium imaging of acute adrenal slices. To prepare the adrenal slices, mice were
anesthetized with isoflurane (1 ml l−1 open drop), followed by cervical dislocation.
Both adrenal glands were rapidly removed and transferred to ice-cold bicarbonate-
buffered saline (BBS: 125 mM NaCl, 2 mM KCl, 26 mM NaHCO3, 0.1 mM CaCl2,
5 mM MgCl2, 10 mM glucose, continuously gassed with 5% CO2/95% O2). Sur-
rounding fat was removed and adrenal glands embedded in 4% low-melting
temperature agarose in BBS. Agarose blocks were mounted on a vibratome
(7000 smz-2, Campden Instruments) and cut into 100–150 µm slices at 4 °C. Slices
were kept at 35 °C for 30 min in BBS, followed by storage for up to 6 h in BBS
supplemented with 2 mM CaCl2 at room temperature. Adrenal slices were placed
in a cell culture insert (Merck Millipore) in one well of a 24 well plate for staining.
The outer reservoir was filled with 800 µl of BBS (supplemented with 2 mM Ca2+).
Calbryte 520 AM (AAT Bioquest) dissolved in DMSO+ 2% Pluronic F-127 was
diluted to a concentration of 9.2 µM in 200 µl BBS (supplemented with 2 mM
Ca2+) and filled into the inner reservoir on top of the adrenal slice. Loading
occurred on top of a heating block set to 37 °C for 1–1.5 h while continuously
gassing the outer reservoir with 5% CO2/95% O2. After dye loading, slices were
transferred to the recording chamber. The chamber was continuously perfused
with recirculating solution from a reservoir gassed with 5% CO2/95% O2 and
heated in line via a heating coil, resulting in a temperature of the perfusion solution
of 33 ± 1 °C. During camera exposure, fluorescence was excited using a blue LED
(pE-300 ultra, CoolLED), passing through a 474/27 nm bandpass filter (AHF
Analysentechnik) and recorded using a 40 × /0.8 NA objective (Olympus), a 432/
523/702 triple-band filter (AHF Analysentechnik) and an OptiMOS camera
(Qimaging). Images were taken every 100 ms with an exposure setting of 10–15 ms.
Regions of interest corresponding to individual cells were chosen manually from
recorded images using Fiji59,60. Criteria for selection were: (1) appearance in glo-
merular structures located near the capsule and (2) visible activity during the
perfusion with 1 nM angiotensin II (AT-II). In total, slices were prepared and
recorded from eight wildtype (4 male, 4 female; 9 slices at 3 mM [K+], 12 slices at
5 mM [K+]) and eight Clcn2R180Q/+ mice (4 male, 4 female; 11 slices at 3 mM [K+]
and 10 slices at 5 mM [K+]).
Calcium signals were extracted and analyzed using a custom Python script
(Supplementary Software 1). Zona glomerulosa calcium signals in acute adrenal
slices were identified based on sudden increases in intracellular calcium
concentration, followed by a slow decay35. For calcium spike detection, background
noise and the signal decay caused by dye bleaching were removed by subtracting
the minimum within a rolling window of 50 frames (5 s). Afterwards, the change in
signal from one time point to the next was calculated to identify spikes generated
by sudden rises of the intracellular calcium concentration. This method allowed for
successful identification of isolated spikes as well as spikes within bursts, even if the
baseline of the calcium concentration did not reach basal levels. To separate true
activity from random background fluctuations, a manually set threshold for spike
registration (above the background level as determined in parts of the recording
without activity) was applied. Remaining artifacts from motion of the slice itself
and perfusion were removed after manual inspection of all detected spikes. The
code and a sample dataset can be found in Supplementary Code 1. Calcium spikes
in zona glomerulosa cells appeared to become more temporally clustered with
increasing AT-II (Fig. 8a, b). To define these clusters of activity (bursts) and
separate them from isolated spikes and one another, we first determined the
intervals between successive calcium spikes. These interspike intervals are shorter
during bursts (one spike quickly follows the next) while they get longer outside of
bursts. Plotting the distribution of the interspike intervals reveals a relatively large
peak towards shorter values (few seconds) corresponding to the typical distances
between spikes during bursting (Supplementary Fig. 9). Increasing [K+] and AT-II
leads to more bursting (Fig. 8) resulting in more recorded interspike intervals
during bursts and thus a more defined distribution at shorter values
(Supplementary Fig. 9). These distributions were similar in Clcn2R180Q/+ and
controls (Supplementary Fig. 9a, b), with a trend towards more bursting at
increasing [K+] and AT-II levels represented by a more defined distribution of
values below 5 s (Supplementary Fig. 9a, b). Based on these interspike interval
distributions, we defined bursts as clusters of activity (with at least three spikes)
containing less than 4 s of quiescence.
Single cell calcium signaling data were analyzed by mixed effect modeling using
the lme456 R package, with individual animals as random and genotypes as fixed
effects with random intercepts. Inclusion of individual slices or sex into the model
did not significantly improve the model as determined by likelihood ratio
comparisons. Significance testing was performed through likelihood ratio test
comparison with a model omitting the fixed effect using a double sided χ2 test.
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Statistics. Raw data were analyzed using Microsoft Office Excel 2016 and
GraphPad Prism 7.00 or 8.2.0 as well as R for blood pressure analysis and calcium
imaging (see above for details). Statistical tests were performed two-sided and are
specified in the figure legends. To account for pseudoreplication, linear mixed
modeling was used in the analysis of blood pressure and imaging data61.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Datasets generated during the current study are included in the article and
supplementary information files, or otherwise available from the corresponding author
upon request.
Code availability
Custom code is available as Supplementary Software 1.
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